Harvard Research Shows Apigenin Blocks CD38 to Boost NAD Levels
A Harvard small molecule screen identified apigenin as a CD38 inhibitor, revealing how this common flavonoid raises cellular NAD levels.
Summary
Researchers at Harvard's small molecule screening facility identified apigenin, a flavonoid found in parsley, chamomile, and celery, as an inhibitor of CD38, an enzyme that degrades NAD. NAD is a critical coenzyme involved in energy metabolism, DNA repair, and aging. As we age, NAD levels decline partly because CD38 activity increases. By blocking CD38, apigenin helps preserve cellular NAD, potentially slowing aspects of metabolic aging. This research, conducted by graduate student Nate Rajman, provided a mechanistic explanation for why apigenin supplementation raises NAD levels in cells. The findings have implications for longevity interventions targeting the NAD pathway, complementing approaches like NMN or NR supplementation. The work also carries a notable backstory involving an academic dispute over research credit.
Detailed Summary
NAD is one of the most studied molecules in longevity science. It powers mitochondrial energy production, fuels DNA repair enzymes called sirtuins and PARPs, and declines steadily with age. Restoring NAD levels has become a central strategy in longevity research, with supplements like NMN and NR gaining widespread attention. But understanding why NAD falls in the first place is equally important.
This Harvard study, conducted through the university's Institute of Chemistry and Cell Biology small molecule screening facility, identified apigenin as a potent inhibitor of CD38, a NADase enzyme that breaks down NAD. CD38 activity rises with age and inflammation, making it a key driver of age-related NAD decline. By screening a library of small molecules, researchers pinpointed apigenin as a compound capable of blocking CD38 and thereby preserving intracellular NAD.
Apigenin is a naturally occurring flavonoid abundant in parsley, chamomile tea, celery, and other common plant foods. Its identification as a CD38 inhibitor provides a mechanistic explanation for earlier observations that apigenin could elevate NAD in cellular models. This positions it alongside pharmaceutical CD38 inhibitors as a potential dietary strategy for supporting NAD metabolism.
The implications are significant for both supplement users and clinicians. Apigenin is inexpensive, widely available, and has a favorable safety profile. If CD38 inhibition is a meaningful lever for raising NAD in humans, apigenin could complement or partially substitute for more expensive NAD precursor supplements.
The research also carries an unusual backstory. David Sinclair publicly noted that the project was conducted by graduate student Nate Rajman, and that credit for the discovery was disputed following collaboration with an outside party. This context raises important questions about academic integrity in competitive longevity research, though it does not diminish the scientific value of the findings.
Key Findings
- Apigenin inhibits CD38, the enzyme responsible for much of the age-related decline in cellular NAD.
- Blocking CD38 with apigenin preserves intracellular NAD, supporting energy metabolism and DNA repair pathways.
- Apigenin is a common dietary flavonoid found in parsley, chamomile, and celery, making it accessible as a supplement.
- This mechanism explains prior observations of NAD elevation following apigenin treatment in cell models.
- CD38 inhibition represents a complementary strategy to NMN or NR supplementation for raising NAD levels.
Methodology
The study used Harvard's ICCB small molecule screening platform to identify CD38 inhibitors from a compound library. Apigenin was identified as a hit and validated for its ability to inhibit NADase activity and raise cellular NAD levels. Specific assay details and cell line information are not available from the abstract alone.
Study Limitations
This summary is based on the abstract and tweet only; the full paper was not accessible for review. Human clinical trial data on apigenin's NAD-boosting effects are limited, and most evidence remains preclinical. The academic dispute surrounding the research's attribution does not affect its scientific validity but adds context worth noting.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.